Important Background Information on TROPION-Breast02

Studying antibody–drug conjugates (ADCs) in patients ineligible for immunotherapy addresses a critical unmet need in PD-L1–negative metastatic TNBC, where targeted treatment options are limited. With only about half of patients receiving second-line therapy, optimizing first-line treatment is essential to improve survival. ADCs, such as datopotamab deruxtecan (Dato-DXd), offer promising mechanisms to expand therapy options, each with distinct pharmacologic features, including differences in target antigens, cytotoxic payloads, and administration schedules. The clinical trial results underscore the potential of ADCs to meaningfully improve outcomes in patients lacking immunotherapy options.